Not Yet RecruitingPhase 1ACTRN12610000363088

Effect of Ascending dose of F-627 in Healthy Male Volunteers

Phase I, Open Labeled, Dose Escalation trial in healthy male subjects to examine the Pharmacokinetics, Pharmacodynamics, and safety of single dose usage of F-627.

Sponsor

Nucleus Network

Enrollment

24 participants

Start Date

May 10, 2010

Study Type

Interventional

Conditions

Neutropenia

Summary

Neutropenia is a complex haematological disorder charactarised by a abnormally low level of neutrophils in the blood. F-627 is being developed to treat neutropenia especially for the management of neutropenia in patients with cancer. F-627 is being developed by Generon (Shanghai) Corporation to provide additional benefits to cancer patients by shortening the duration and lessening the severity of neutropenia after chemotherapy. The purpose of this study is to researech the safety of the use of F-627 in Healthy Male Volunteers. There will be no benefits from participating in this trial, Patients will receive only one dose of study drug.

Eligibility

Sex: MalesMin Age: 18 YearssMax Age: 45 Yearss

Inclusion Criteria3

Subjects must be healthy male volunteers
Subjects must have a body mass index greater than or equal to 19 (kg/m2)and less than or equal to 34 (kg/m2).
No clinically significant findings in the medical and physical examination, especially normal full blood count (at screening), hepatic and renal function.

Exclusion Criteria6

Family history of premature CHD (Coronary Heart Disease)
Any condition which can cause splenomegaly
Exposure to prescription medications or to drugs known to interfere with metabolism of drugs within 30 days prior to screening
Prior history of a haematological malignancy, or current history of a haematological disorder (even if it does not require treatment)
Any abnormality of red cell count, mean corpuscular volume,platelet count, white cell count or white cell differential
Subjects at risk of tuberculosis (TB)

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

Ascending dose of F-627 Cohort 1 will receive 30ug/kg F-627 in a single subcutaneous dose Cohort 2 will receive 60ug/kg F-627 in a single subcutaneous dose Cohort 3 will receive 120ug/kg F-627 in a

Ascending dose of F-627 Cohort 1 will receive 30ug/kg F-627 in a single subcutaneous dose Cohort 2 will receive 60ug/kg F-627 in a single subcutaneous dose Cohort 3 will receive 120ug/kg F-627 in a single subcutaneous dose Cohort 4 will receive 240ug/kg F-627 in a single subcutaneous dose